We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Docetaxel Improves Survival in Node-Positive Early-Stage Breast Cancer Patients

Aug 1, 2002
Volume: 
16
Issue: 
8
  • Breast Cancer, Breast Cancer

Women with early-stage breast cancer treated with a
docetaxel (Taxotere)-based regimen after surgery had a 32% less chance of
developing disease recurrence than did women receiving one of the most effective
adjuvant treatments currently available. Results from the Breast Cancer
International Research Group (BCIRG) trial 001, the first phase III trial to
evaluate docetaxel after breast surgery, were presented at the recent annual
meeting of the American Society of Clinical Oncology (ASCO) by the BCIRG.

Benefits Favor One Group

In the analysis of the study, women were divided into two groups—those with
one to three positive lymph nodes and those with four or more. The most
significant benefit from the use of docetaxel was seen in women with one to
three positive lymph nodes. Among these women, treatment with docetaxel reduced
the risk of relapse by 50% and the mortality rate by 54%. Women with one to
three positive lymph nodes account for 60% to 70% of all women worldwide with
node-positive early-stage breast cancer.

"The superior results observed with the docetaxel-based regimen indicate
that it can potentially cure more women than one of the best chemotherapies we
have," said Jean-Marc Nabholtz, MD, chairman of the BCIRG, study chairman,
professor of medicine at the University of California at Los Angeles (UCLA), and
director of the Cancer Therapy Development Program at the Jonsson Comprehensive
Cancer Center at UCLA. "Although early, these results should be considered
when choosing therapy for a large number of women with early breast
cancer."

Study Demographics

The BCIRG 001 study was designed to determine whether docetaxel would also
benefit women with early-stage disease. After surgery, study participants
received either the TAC regimen (docetaxel, doxorubicin [Adriamycin],
cyclophosphamide [Cytoxan, Neosar]) or the standard FAC regimen (fluorouracil,
doxorubicin, cyclophosphamide). Of the 1,491 women enrolled in the study, 745
were randomized to the TAC arm and 746 to the FAC arm.

Nearly 3 years after treatment, study results show that 82% of patients in
the TAC arm and 74% in the FAC arm were alive and disease-free. For those
treated with TAC, this represents a significant improvement in disease-free
survival and a 32% reduction in the risk of recurrence (P = .0011)
compared to those treated with FAC. In addition, women in the TAC arm had nearly
a 50% less chance of developing a metastatic relapse.

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.